D-galactose (AVTX-801) / Avalo Therap - LARVOL DELTA

Evaluating the Efficacy and Safety of D-galactose in PGM1-CDG (AVTX-801) (clinicaltrials.gov) - P2 | N=8 | Not yet recruiting | Sponsor: Eva Morava-Kozicz | Trial completion date: Dec 2025 ➔ Mar 2028 | Trial primary completion date: Dec 2025 ➔ Mar 2028

Trial completion date • Trial primary completion date

AVTX-801 D-galactose Supplementation in SLC35A2-CDG (clinicaltrials.gov) - P2 | N=10 | Not yet recruiting | Sponsor: Eva Morava-Kozicz | Trial completion date: Aug 2026 ➔ Mar 2028 | Trial primary completion date: Aug 2026 ➔ Mar 2028

Trial completion date • Trial primary completion date

AVTX-801 D-galactose Supplementation in SLC35A2-CDG (clinicaltrials.gov) - P2 | N=10 | Not yet recruiting | Sponsor: Eva Morava-Kozicz | N=20 ➔ 10 | Trial completion date: Jan 2025 ➔ Aug 2026 | Trial primary completion date: Jan 2025 ➔ Aug 2026

Enrollment change • Trial completion date • Trial primary completion date

Evaluating the Efficacy and Safety of D-galactose in PGM1-CDG (AVTX-801) (clinicaltrials.gov) - P2 | N=8 | Not yet recruiting | Sponsor: Eva Morava-Kozicz | Trial completion date: Mar 2025 ➔ Dec 2025 | Trial primary completion date: Mar 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date

AVTX-801: Evaluate Optimal Dosing and Long-term Safety of D-galactose in PGM1-CDG (clinicaltrials.gov) - P2 | N=9 | Not yet recruiting | Sponsor: Eva Morava-Kozicz | Phase classification: P2b ➔ P2 | Trial completion date: Nov 2024 ➔ Mar 2025 | Trial primary completion date: Nov 2024 ➔ Mar 2025

Phase classification • Trial completion date • Trial primary completion date

AVTX-801: Evaluate Optimal Dosing and Long-term Safety of D-galactose in PGM1-CDG (clinicaltrials.gov) - P2b | N=9 | Not yet recruiting | Sponsor: Eva Morava-Kozicz | Phase classification: P1 ➔ P2b | Trial completion date: Jun 2024 ➔ Nov 2024 | Trial primary completion date: Jun 2024 ➔ Nov 2024

Phase classification • Trial completion date • Trial primary completion date

AVTX-801 D-galactose Supplementation in SLC35A2-CDG (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: Eva Morava-Kozicz | Phase classification: P2/3 ➔ P2 | N=10 ➔ 20 | Trial completion date: Jun 2024 ➔ Jan 2025 | Trial primary completion date: Jun 2024 ➔ Jan 2025

Enrollment change • Phase classification • Trial completion date • Trial primary completion date

AVTX-801 D-galactose Supplementation in SLC35A2-CDG (clinicaltrials.gov) - P2/3 | N=10 | Not yet recruiting | Sponsor: Eva Morava-Kozicz | Trial completion date: Sep 2024 ➔ Jun 2024 | Initiation date: Oct 2022 ➔ May 2023

Trial completion date • Trial initiation date • IGF1

AVTX-801: Evaluate Optimal Dosing and Long-term Safety of D-galactose in PGM1-CDG (clinicaltrials.gov) - P1 | N=9 | Not yet recruiting | Sponsor: Eva Morava-Kozicz | Trial completion date: Sep 2024 ➔ Jun 2024 | Initiation date: Oct 2022 ➔ Jun 2023

Trial completion date • Trial initiation date • IGF1 • IGFBP3

AVTX-801: Evaluate Optimal Dosing and Long-term Safety of D-galactose in PGM1-CDG (clinicaltrials.gov) - P1 | N=9 | Not yet recruiting | Sponsor: Eva Morava-Kozicz | Phase classification: P2/3 ➔ P1 | Trial completion date: Dec 2024 ➔ Sep 2024 | Trial primary completion date: Sep 2024 ➔ Jun 2024

Phase classification • Trial completion date • Trial primary completion date • IGF1 • IGFBP3

AVTX-801 D-galactose Supplementation in SLC35A2-CDG (clinicaltrials.gov) - P2/3 | N=10 | Not yet recruiting | Sponsor: Eva Morava-Kozicz | Trial completion date: Mar 2025 ➔ Sep 2024 | Trial primary completion date: Nov 2024 ➔ Jun 2024

Trial completion date • Trial primary completion date • IGF1

A Multicenter, Randomized, Double-blind, Withdrawal Trial Assessing the Efficacy, Safety, and Tolerability of AVTX-801 in Subjects With PGM1-CDG (clinicaltrials.gov) - P2/3 | N=9 | Not yet recruiting | Sponsor: Eva Morava-Kozicz

New P2/3 trial • IGF1 • IGFBP3

A Multicenter, Open-Label, Withdrawal and Treatment Trial Assessing the Efficacy, Safety, and Tolerability of Doses of CERC-801 in Subjects With SLC35A2-CDG (clinicaltrials.gov) - P2/3 | N=10 | Not yet recruiting | Sponsor: Eva Morava-Kozicz

New P2/3 trial • IGF1